Literature DB >> 18644071

Long-term adherence to statin treatment in diabetes.

L A Donnelly1, A S F Doney, A D Morris, C N A Palmer, P T Donnan.   

Abstract

AIMS: To determine the patterns and predictors of long-term adherence to statin therapy in all patients with diabetes in the community setting.
METHODS: We retrospectively studied patients with diabetes who were resident in Tayside, Scotland from 1 January 1989 to 31 May 2003 and initiated statin treatment during that time. The main outcome measure was percentage of days covered (PDC) by a statin, calculated at regular intervals. Predictors of suboptimal adherence (PDC < 80%) were identified using generalized linear models for repeated measures.
RESULTS: Six thousand four hundred and sixty-two patients were included in the study. In the first year, the mean PDC was 87, 61% in the first and second quarter, respectively, and 65% after 13 years. Less than 50% of patients maintained a PDC of > 80% after 13 years. Predictors of poor long-term adherence were younger age, higher HbA(1c), no history of smoking, no cardiovascular morbidity at baseline and occurrence of cardiovascular disease after statin commencement.
CONCLUSIONS: This study suggests that barriers to long-term adherence to statins tend to arise early on in the therapeutic course. In general, long-term adherence is poor in patients with diabetes, especially among those with few other cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644071     DOI: 10.1111/j.1464-5491.2008.02476.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  29 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 2.  Predictors of statin adherence.

Authors:  Alexander Mauskop; William B Borden
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

3.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

4.  Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study.

Authors:  Päivi Ruokoniemi; Maarit J Korhonen; Arja Helin-Salmivaara; Piia Lavikainen; Antti Jula; Seppo Y T Junnila; Raimo Kettunen; Risto Huupponen
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

5.  Medication Nonadherence: The Role of Cost, Community, and Individual Factors.

Authors:  Ibrahim Abbass; Lee Revere; Jordan Mitchell; Ajit Appari
Journal:  Health Serv Res       Date:  2016-08-25       Impact factor: 3.402

6.  Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.

Authors:  L A Donnelly; A S F Doney; R Tavendale; C C Lang; E R Pearson; H M Colhoun; M I McCarthy; A T Hattersley; A D Morris; C N A Palmer
Journal:  Clin Pharmacol Ther       Date:  2010-12-22       Impact factor: 6.875

Review 7.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

8.  Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.

Authors:  Richard H Chapman; Jason Yeaw; Craig S Roberts
Journal:  BMC Cardiovasc Disord       Date:  2010-06-17       Impact factor: 2.298

9.  Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?

Authors:  Richard H Chapman; Elise M Pelletier; Paula J Smith; Craig S Roberts
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

10.  Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications 1997- 2006.

Authors:  H Dominguez; T K Schramm; M L Norgaard; S Z Abildstrøm; L Kober; C Jørgensen; T J Guterbaum; H E Poulsen; C Torp-Pedersen; G H Gislason
Journal:  Open Cardiovasc Med J       Date:  2009-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.